MS4A6A and central nervous system cancer: Moreover, according to K-M plots, the survival differences were still obvious after grouping by MS4A6A expression and clinicopathologic subgroups (log-rank test, p < 0.001; Figures 4A–F, Figures S6A–F and Figures S7A–F), demonstrating that the MS4A6A expression level might play an important role in glioma OS classification.